Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Pacira Biosciences Inc's Business Segments
Pacira Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 192
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 192 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Product99%
- EXPAREL76.8%
- ZILRETTA17%
- iovera°3.5%
- Bupivacaine liposome injectable suspension1.7%
- Royalty1%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 190 | 99% |
| EXPAREL | $ 148 | 76.8% |
| ZILRETTA | $ 33 | 17% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Pacira Biosciences Inc dataset.
Description of Pacira Biosciences Inc
Pacira Biosciences Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative drug therapies that enhance patient outcomes. The company's portfolio includes best-in-class regional anesthesia and analgesia products, as well as long-acting local anesthetic formulations for postoperative pain management.
The company was founded in 2006 as Pacira Pharmaceuticals, Inc. and is headquartered in Parsippany, New Jersey. It has grown rapidly in recent years, with a strong track record of clinical research and development, as well as a commitment to sustainability and social responsibility.
One of Pacira's flagship products is Exparel, a long-acting, liposome-based local anesthetic that provides up to 72 hours of pain relief following surgery. Exparel has been approved by the FDA for a wide variety of surgical procedures, and is considered a safe and effective alternative to traditional opioid-based pain management strategies.
Pacira's other products include DepoCyt(e), a chemotherapy drug for the treatment of lymphomatous meningitis, and iovera, a non-opioid, non-invasive pain management system that uses cold therapy to block nerve signals and provide pain relief.
In addition to its pharmaceutical products, Pacira is also committed to sustainability and social responsibility. The company has implemented several initiatives aimed at reducing its environmental impact, including a zero-waste program and efforts to minimize energy and water usage. It also supports a range of philanthropic causes, including organizations focused on cancer research and patient advocacy.
Overall, Pacira Biosciences Inc. is a cutting-edge pharmaceutical company that is pioneering innovative drug therapies for pain management and making significant progress in achieving sustainable and socially responsible business practices.
The company was founded in 2006 as Pacira Pharmaceuticals, Inc. and is headquartered in Parsippany, New Jersey. It has grown rapidly in recent years, with a strong track record of clinical research and development, as well as a commitment to sustainability and social responsibility.
One of Pacira's flagship products is Exparel, a long-acting, liposome-based local anesthetic that provides up to 72 hours of pain relief following surgery. Exparel has been approved by the FDA for a wide variety of surgical procedures, and is considered a safe and effective alternative to traditional opioid-based pain management strategies.
Pacira's other products include DepoCyt(e), a chemotherapy drug for the treatment of lymphomatous meningitis, and iovera, a non-opioid, non-invasive pain management system that uses cold therapy to block nerve signals and provide pain relief.
In addition to its pharmaceutical products, Pacira is also committed to sustainability and social responsibility. The company has implemented several initiatives aimed at reducing its environmental impact, including a zero-waste program and efforts to minimize energy and water usage. It also supports a range of philanthropic causes, including organizations focused on cancer research and patient advocacy.
Overall, Pacira Biosciences Inc. is a cutting-edge pharmaceutical company that is pioneering innovative drug therapies for pain management and making significant progress in achieving sustainable and socially responsible business practices.
Pacira Biosciences Inc. stands out in the pharmaceutical landscape as a pioneering company focused on the development and commercialization of innovative solutions specifically dedicated to pain management and postsurgical care. The companys commitment to addressing the opioid crisis while providing effective pain relief options has positioned it as a significant player in healthcare. Below is an extensive description of the segments, products, and services that Pacira Biosciences Inc. offers.
Segments:
1. EXPAREL Segment:
- Overview: At the heart of Paciras offerings is EXPAREL, a non-opioid, long-acting local anesthetic designed to provide effective pain relief following surgical procedures. It employs a unique delivery system that extends the duration of pain relief, allowing patients to manage postoperative pain without the need for narcotics.
- Application: EXPAREL is primarily utilized in various surgical settings including hospitals, ambulatory surgery centers, and outpatient facilities. Its application spans multiple specialties such as orthopedic surgery, general surgery, and plastic surgery.
2. IV and Regional Anesthetics Segment:
- Overview: This segment encompasses additional pharmaceutical formulations that provide localized anesthesia. Pacira leverages advanced drug delivery systems to create formulations that yield long-lasting analgesia, thereby enhancing patient comfort and postoperative recovery.
- Key Products:
- DEXPATM: This long-acting anesthetic is aimed to relieve pain for extended periods (up to 72 hours), proving advantageous in surgical scenarios that typically involve significant postoperative discomfort. It particularly shines in comprehensive procedures such as spine surgeries and knee replacements.
- DepofoamTM: Incorporating the innovative Depofoam technology, this product allows for a controlled and prolong release of the anesthetic. Depofoam serves as a delivery platform that enhances patient outcomes by improving pain management post-surgery, applicable in challenging surgical contexts.
Products:
1. EXPAREL:
- Mechanism: EXPAREL utilizes liposomal encapsulation to deliver bupivacaine, creating an effective barrier against pain signals for an extended duration. This mechanism decreases the urge for running through a typical opioid pathway in managing pain.
- Benefits: By minimizing reliance on opioids, EXPAREL not only improves patient experiences but also addresses the broader healthcare challenge of opioid-related side effects and dependency.
2. DEXPATM:
- Functionality: With its ability to provide pain relief lasting up to three days, DEXPATM becomes instrumental in surgeries known for aftercare complexities. It is vital in ensuring patient comfort and reducing hospital stays, leading to better outcomes in recovery trajectories.
3. DepofoamTM:
- Advantages: The unique Depofoam technology enables a predictable release profile that can be tailored to various surgical needs. This product is indicative of Pacira’s commitment to not merely treating pain but transitioning to a holistic approach to healthcare.
Services:
1. Pain Management Education:
- Target Audience: This initiative is geared towards healthcare professionals—surgeons, anesthesiologists, and nurses—equipping them with knowledge centered on pain management strategies. The aim is to foster an understanding of the operational use of Pacira’s products and enhancing overall patient care.
2. Clinical Support:
- Patient Resources: Pacira provides comprehensive resources for patients that encompass educational materials, personalized care plans, and direct channels for patient inquiries. By doing so, the company ensures patients are well-informed about their pain management options, enhancing their confidence in the postoperative phase.
3. Healthcare Provider Collaboration:
- Partnerships: The company takes a collaborative approach by working directly with healthcare institutions to integrate products into their pain management protocols, enabling optimized care pathways that highlight the importance of multimodal analgesia.
Overall Impact:
Pacira Biosciences Inc. is not just focused on product development but is integral to shaping the future of pain management strategies. The companys emphasis on innovative, non-opioid solutions allows for substantial progress in how postoperative pain is managed, fostering a safer environment for surgical patients. This progressive approach to medication and support services signifies a transformative shift in pharmaceutical practices, with Pacira at the forefront of delivering solutions aimed at improving recovery, enhancing the quality of life, and minimizing the risks associated with traditional opioid medications.
Segments:
1. EXPAREL Segment:
- Overview: At the heart of Paciras offerings is EXPAREL, a non-opioid, long-acting local anesthetic designed to provide effective pain relief following surgical procedures. It employs a unique delivery system that extends the duration of pain relief, allowing patients to manage postoperative pain without the need for narcotics.
- Application: EXPAREL is primarily utilized in various surgical settings including hospitals, ambulatory surgery centers, and outpatient facilities. Its application spans multiple specialties such as orthopedic surgery, general surgery, and plastic surgery.
2. IV and Regional Anesthetics Segment:
- Overview: This segment encompasses additional pharmaceutical formulations that provide localized anesthesia. Pacira leverages advanced drug delivery systems to create formulations that yield long-lasting analgesia, thereby enhancing patient comfort and postoperative recovery.
- Key Products:
- DEXPATM: This long-acting anesthetic is aimed to relieve pain for extended periods (up to 72 hours), proving advantageous in surgical scenarios that typically involve significant postoperative discomfort. It particularly shines in comprehensive procedures such as spine surgeries and knee replacements.
- DepofoamTM: Incorporating the innovative Depofoam technology, this product allows for a controlled and prolong release of the anesthetic. Depofoam serves as a delivery platform that enhances patient outcomes by improving pain management post-surgery, applicable in challenging surgical contexts.
Products:
1. EXPAREL:
- Mechanism: EXPAREL utilizes liposomal encapsulation to deliver bupivacaine, creating an effective barrier against pain signals for an extended duration. This mechanism decreases the urge for running through a typical opioid pathway in managing pain.
- Benefits: By minimizing reliance on opioids, EXPAREL not only improves patient experiences but also addresses the broader healthcare challenge of opioid-related side effects and dependency.
2. DEXPATM:
- Functionality: With its ability to provide pain relief lasting up to three days, DEXPATM becomes instrumental in surgeries known for aftercare complexities. It is vital in ensuring patient comfort and reducing hospital stays, leading to better outcomes in recovery trajectories.
3. DepofoamTM:
- Advantages: The unique Depofoam technology enables a predictable release profile that can be tailored to various surgical needs. This product is indicative of Pacira’s commitment to not merely treating pain but transitioning to a holistic approach to healthcare.
Services:
1. Pain Management Education:
- Target Audience: This initiative is geared towards healthcare professionals—surgeons, anesthesiologists, and nurses—equipping them with knowledge centered on pain management strategies. The aim is to foster an understanding of the operational use of Pacira’s products and enhancing overall patient care.
2. Clinical Support:
- Patient Resources: Pacira provides comprehensive resources for patients that encompass educational materials, personalized care plans, and direct channels for patient inquiries. By doing so, the company ensures patients are well-informed about their pain management options, enhancing their confidence in the postoperative phase.
3. Healthcare Provider Collaboration:
- Partnerships: The company takes a collaborative approach by working directly with healthcare institutions to integrate products into their pain management protocols, enabling optimized care pathways that highlight the importance of multimodal analgesia.
Overall Impact:
Pacira Biosciences Inc. is not just focused on product development but is integral to shaping the future of pain management strategies. The companys emphasis on innovative, non-opioid solutions allows for substantial progress in how postoperative pain is managed, fostering a safer environment for surgical patients. This progressive approach to medication and support services signifies a transformative shift in pharmaceutical practices, with Pacira at the forefront of delivering solutions aimed at improving recovery, enhancing the quality of life, and minimizing the risks associated with traditional opioid medications.